2-((naphthalen-1-yl(phenyl)methoxy)methyl)oxirane | 1173292-10-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-((naphthalen-1-yl(phenyl)methoxy)methyl)oxirane
• 英文别名: 2-(napthalen-1-yl-phenyl-methoxymethyl)-oxirane；2-[[Naphthalen-1-yl(phenyl)methoxy]methyl]oxirane
• CAS: 1173292-10-8
• 化学式: C₂₀H₁₈O₂
• 分子量: 290.362
• InChiKey: VYLIBMMLJVLVGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯基)哌嗪 、 2-((naphthalen-1-yl(phenyl)methoxy)methyl)oxirane 以 异丙醇 为溶剂， 反应 16.0h， 以23%的产率得到1-(4-(4-chlorophenyl)piperazin-1-yl)-3-(naphthalen-1-yl(phenyl)methoxy)propan-2-ol
  参考文献：
  名称：

  Novel quinoline and naphthalene derivatives as potent antimycobacterial agents

  摘要：

  We have designed and synthesized both the quinoline and naphthalene based molecules influenced by the unique structural make-up of mefloquine and TMC207, respectively. These compounds were evaluated for their anti-mycobacterial activity against drug sensitive Mycobacterium tuberculosis H37Rv in vitro at single-dose concentration (6.25 mu g/mL). The compounds 22,23, 26 and 27 inhibited the growth of M. tuberculosis H37Rv 99%, 90%, 98% and 91% respectively. Minimum inhibitory concentration of compounds 22, 23, 26 and 27 was found to be 6.25 mu g/mL.. Our molecular modeling and docking studies of designed compounds showed hydrogen bonding with Glu-61, Tyr-64 and Asn-190 amino acid residues at the putative binding site of ATP synthase, these interactions were coherent as shown by Mefloquine and TMC207, where hydrogen bonding was found with Tyr-64 and Glu-61 respectively. SAR analysis indicates importance of hydroxyl group and nature of substituents on piperazinyl-phenyl ring was critical in dictating the biological activity of newly synthesized compounds. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.01.024
• 作为产物：
  描述：

  萘-1-基(苯基)甲醇 、 环氧氯丙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 以52%的产率得到2-((naphthalen-1-yl(phenyl)methoxy)methyl)oxirane
  参考文献：
  名称：

  Novel quinoline and naphthalene derivatives as potent antimycobacterial agents

  摘要：

  We have designed and synthesized both the quinoline and naphthalene based molecules influenced by the unique structural make-up of mefloquine and TMC207, respectively. These compounds were evaluated for their anti-mycobacterial activity against drug sensitive Mycobacterium tuberculosis H37Rv in vitro at single-dose concentration (6.25 mu g/mL). The compounds 22,23, 26 and 27 inhibited the growth of M. tuberculosis H37Rv 99%, 90%, 98% and 91% respectively. Minimum inhibitory concentration of compounds 22, 23, 26 and 27 was found to be 6.25 mu g/mL.. Our molecular modeling and docking studies of designed compounds showed hydrogen bonding with Glu-61, Tyr-64 and Asn-190 amino acid residues at the putative binding site of ATP synthase, these interactions were coherent as shown by Mefloquine and TMC207, where hydrogen bonding was found with Tyr-64 and Glu-61 respectively. SAR analysis indicates importance of hydroxyl group and nature of substituents on piperazinyl-phenyl ring was critical in dictating the biological activity of newly synthesized compounds. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.01.024

文献信息

• [EN] QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE QUINOLÉINE, DE NAPHTALÈNE, DE QUINOLÉINE OU DE NAPHTALÈNE CONTRAINT AU NIVEAU CONFORMATION EN TANT QU'AGENTS ANTIMYCOBACTÉRIENS
  申请人：CHATTOPADHYAYA JYOTI

  公开号：WO2009091324A1

  公开（公告）日：2009-07-23

  The invention relates to a compound of general formula I, II, III, IV, V, VI, VII, VIII, IX, X or a tautomer and the stereochemically isomeric forms thereof or pharmaceutically acceptable salts thereof, a N-oxide form thereof or a pro-drug thereof. The compound is usable as a medicament for the treatment of mycobacterial disease.

  该发明涉及一般式I、II、III、IV、V、VI、VII、VIII、IX、X的化合物，或其立体化学异构体或药学上可接受的盐，其N-氧化物形式或其前药。该化合物可用作治疗分枝杆菌病的药物。
• QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS
  申请人：Chattopadhyaya Jyoti

  公开号：US20110059948A1

  公开（公告）日：2011-03-10

  The invention relates to a compound of general formula I, II, III, IV, V, VI, VII, VIII, IX, X or a tautomer and the stereochemically isomeric forms thereof or pharmaceutically acceptable salts thereof, a N-oxide form thereof or a pro-drug thereof. The compound is usable as a medicament for the treatment of mycobacterial disease.

  本发明涉及一种符合以下公式I、II、III、IV、V、VI、VII、VIII、IX、X或其互变异构体，或其药学上可接受的盐、N-氧化物形式或前药的化合物。该化合物可用作治疗分枝杆菌病的药物。
• Novel quinoline and naphthalene derivatives as potent antimycobacterial agents
  作者：Ram Shankar Upadhayaya、Jaya Kishore Vandavasi、Ramakant A. Kardile、Santosh V. Lahore、Shailesh S. Dixit、Hemantkumar S. Deokar、Popat D. Shinde、Manash P. Sarmah、Jyoti Chattopadhyaya

  DOI：10.1016/j.ejmech.2010.01.024

  日期：2010.5

  We have designed and synthesized both the quinoline and naphthalene based molecules influenced by the unique structural make-up of mefloquine and TMC207, respectively. These compounds were evaluated for their anti-mycobacterial activity against drug sensitive Mycobacterium tuberculosis H37Rv in vitro at single-dose concentration (6.25 mu g/mL). The compounds 22,23, 26 and 27 inhibited the growth of M. tuberculosis H37Rv 99%, 90%, 98% and 91% respectively. Minimum inhibitory concentration of compounds 22, 23, 26 and 27 was found to be 6.25 mu g/mL.. Our molecular modeling and docking studies of designed compounds showed hydrogen bonding with Glu-61, Tyr-64 and Asn-190 amino acid residues at the putative binding site of ATP synthase, these interactions were coherent as shown by Mefloquine and TMC207, where hydrogen bonding was found with Tyr-64 and Glu-61 respectively. SAR analysis indicates importance of hydroxyl group and nature of substituents on piperazinyl-phenyl ring was critical in dictating the biological activity of newly synthesized compounds. (C) 2010 Elsevier Masson SAS. All rights reserved.